Phase III study confirms Kyprolis regimen extends overall survival In patients with relapsed multiple myeloma

ENDEAVOR study long-term data show Kyprolis and dexamethasone reduced the risk of death by 24% versus Velcade and dexamethasone.

"For physicians making prescribing decisions, long-term follow-up helps to further support the safety and efficacy of a therapy and instills confidence in the treatment," said Robert Orlowski, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. "The current three-year follow-up analysis demonstrates that this proteasome inhibitor continues to demonstrate a prolonged overall survival benefit and consistent safety profile when combined with dexamethasone for relapsed multiple myeloma patients."

"We are excited about the 3-year follow-up of the ENDEAVOR study as the overall survival benefit reflects both the efficacy and the long-term safety of this Kyprolis regimen in patients with relapsed multiple myeloma," said Sean E. Harper, executive vice president of R&D at Amgen. "These results confirm that when a patient relapses, Kyprolis should replace Velcade as a standard-of-care."